SCHEMBL2309935

SCHEMBL2309935

O=C(O)c1cc2cc(Cl)ccc2nc1N[C@@H](CO)Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 2/20 0.49
MAPT P10636 2/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49
EGFR P00533 2/20 0.48
HDAC8 Q9BY41 2/20 0.43
JAK3 P52333 2/20 0.40
IRAK4 Q9NWZ3 2/20 0.40
PTGS2 P35354 1/20 0.40
PYGL P06737 2/20 0.39
PRNP P04156 1/20 0.39
CYP3A4 P08684 1/20 0.38
MAPK1 P28482 1/20 0.38
PLA2G2A P14555 1/20 0.38
ADORA1 P30542 1/20 0.38
PDK1 Q15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2310615 1.00 KDM4E (0.49) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL2358959 1.00 KDM4E (0.49) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL2310490 0.85 PYGL (0.47) MEN1KMT2AALDH1A1HDAC8PYGL
SCHEMBL2314270 0.85 PYGL (0.47) MEN1KMT2AALDH1A1HDAC8PYGL
SCHEMBL2313404 0.83 ELANE (0.45) MEN1KMT2AHDAC8PYGLPRNP
SCHEMBL2311951 0.82 RXFP1 (0.41) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL2308610 0.82 ITGB2 (0.48) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL2311758 0.82 PHGDH (0.45) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL2306529 0.82 PHGDH (0.45) KDM4EMEN1MAPTKMT2AALDH1A1
SCHEMBL2310351 0.82 PYGL (0.51) MEN1KMT2AHDAC8PYGLPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288549-B2 Glycine B antagonist MERZ PHARMA GMBH & CO. KGAA (DE) 2012-10-16 US claimed
US-20110190342-A1 GLYCINE B ANTAGONIST HENRICH MARKUS 2011-08-04 US claimed
EP-2350014-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2011-08-03 EP claimed
WO-2010037533-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA (DE) 2010-04-08 WO claimed
US-8288549-B2 Glycine B antagonist MERZ PHARMA GMBH & CO. KGAA (DE) 2012-10-16 US disclosed
US-20110190342-A1 GLYCINE B ANTAGONIST HENRICH MARKUS 2011-08-04 US disclosed
EP-2350014-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2011-08-03 EP disclosed
WO-2010037533-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA (DE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190342-A1 GLYCINE B ANTAGONIST GRIN2B, GLRB, GRIN2A KDM4E 3958/4885MEN1 808/4885MAPT 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.